We applaud the Sept. 2 op-ed by Rep. Karen Bass (D-Calif.) regarding the importance of promoting diversity in the clinical trial patient population [“Vaccine trials’ lack of diversity threatens their validity”]. It’s the right thing to do morally, and it will strengthen trial success rates by enhancing data and better mirroring the people our drugs and treatments are designed to help.
Source: washingtonpost.com
